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Background: Epidermal Growth Factor Receptor (EGFR) targeting therapies are currently of great relevance for the
treatment of lung cancer. For this reason, in addition to mutational analysis immunohistochemistry (IHC) of EGFR in
lung cancer has been discussed for the decision making of according therapeutic strategies. The aim of this study
was to obtain standardization of EGFR-expression methods for the selection of patients who might benefit of EGFR
targeting therapies.
Methods: As a starting point of a broad investigation, aimed at elucidating the expression of EGFR on different
biological levels, four EGFR specific antibodies were analyzed concerning potential differences in expression levels by
Immunohistochemistry (IHC) and correlated with fluorescence in situ hybridization (FISH) analysis and clinicopathological
data. 206 tumor tissues were analyzed in a tissue microarray format employing immunohistochemistry with four
different antibodies including Dako PharmDx kit (clone 2-18C9), clone 31G7, clone 2.1E1 and clone SP84 using three
different scoring methods. Protein expression was compared to FISH utilizing two different probes.
Results: EGFR protein expression determined by IHC with Dako PharmDx kit, clone 31G7 and clone 2.1E1 (p ≤ 0.05)
correlated significantly with both FISH probes independently of the three scoring methods; best correlation is shown
for 31G7 using the scoring method that defined EGFR positivity when ≥ 10% of the tumor cells show membranous
staining of moderate and severe intensity (p = 0.001).
Conclusion: Overall, our data show differences in EGFR expression determined by IHC, due to the applied antibody.
Highest concordance with FISH is shown for antibody clone 31G7, evaluated with score B (p = 0.001). On this account,
this antibody clone might by utilized for standard evaluation of EGFR expression by IHC.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
13000_2014_165.
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Lung cancer is the leading cause of death related to
cancer in the world according to WHO data published
in December 2013. Non-small cell lung cancer (NSCLC)
accounts about 85% of all lung cancers [1]. Despite
therapeutic advances, the overall 5-year survival is only* Correspondence: i.watermann@lungenclinic.de
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unless otherwise stated.15% [2]. EGFR is a cell surface tyrosine kinase receptor
abundantly expressed on all epithelial and stromal cells
[3]. Expression of EGFR is deregulated in a variety of solid
tumors and has been correlated with disease progression
and poor survival [4]. In 34% to 84% of NSCLC patients,
EGFR overexpression is also detectable; an increased
expression of EGFR is proposed to be of prognostic and
also of potential predictive relevance [5]. High EGFR gene
copy numbers are found in almost 60% of the patients [6].
Based on its central role in cellular tumor growth, EGFR
is intended as favored drug target for the development
of specific anti-NSCLC treatments [7]. Plenty of EGFRtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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clinical trials; including specific antibodies such as
cetuximab and necitumumab, as well as small molecule
tyrosine kinase inhibitors (TKI) like erlotinib, afatinib,
and gefitinib [8]. The identification of patients who might
profit from these selective drugs is of tremendous interest.
Although EGFR targeted therapies have been approved,
there exists no general consensus concerning the evalu-
ation of EGFR expression patterns in NSCLC. As shown
in the FLEX-study (First Line Treatment for Patients
with EGFR-expressing Advanced NSCLC), high EGFR
H-scores can predict survival benefit for cetuximab
plus first-line chemotherapy in patients with advanced
NSCLC [9]. Due to the prognostic role of EGFR and
the relevance of determination the EGFR expression
status as well as the identification of EGFR mutations
to select individual therapies for lung cancer patients,
the evaluation of lung carcinomas require the optimal
characterization of clinical sections in routine histopath-
ology. Thus, it is of great relevance to determine the
specific EGFR status to identify patients for appropriate
therapies. With the ongoing progress in generation of
EGFR-specific therapeutics, pathologists have to employ
standardized protocols for defined antibodies used for
immunohistochemical detection of EGFR expression as
well as consistent scoring systems. So far, determination
of EGFR status was performed by immunohistochemis-
try on paraffin-embedded tumor specimens to select
patients suitable for EGFR-specific therapies. However,
this method depends highly on the choice of the first
antibody and the applied scoring method [10]. Since
there are no data available concerning optimal selection
of antibody used for diagnostic approaches, we compared
four commercially available EGFR-specific antibodies and
three different scoring systems concerning their disparities
in immunohistochemical evaluation to obtain insight
which variant comes off best for the determination of
EGFR expression in NSCLC.
There are inconsistent data for the relationship between
EGFR expression on protein level and response to EGFR
specific therapies [11]. Nevertheless, an increased EGFR
gene copy number has recently been proposed as pre-
dictor of anti EGFR targeted therapies in lung cancer
patients [6]. The evaluation of EGFR gene status by
FISH is delicate: EGFR gene variations in tumor cells
are focal and low levels of EGFR amplification are difficult
to visualize. As a start of an investigation, aimed to identify
enlarged collectives of patients who might benefit from
TKI treatment additionally to those, bearing activating
mutations, we evaluated IHC-based methods to optimize
the detection of EGFR expression on protein level using
different fixation procedures. First, we analyzed immu-
nohistochemistry and FISH in formalin-fixed, paraffin-
embedded tissues (FFPE). FISH analysis was performedby application of two different probes to evaluate the
EGFR gene status. Data were correlated with EGFR
expression on protein level determined by IHC, in order
to figure out the predictive value of EGFR expression on
protein level and gene amplification status. Data of IHC
and FISH analysis were correlated with clinicopatholog-
ical data to find out, whether IHC could be the method
of choice, probably coupled to FISH analysis. Thus, the
objectives of these studies were first to investigate different
antibodies and scoring systems in immunohistochemistry
and the comparison of two different FISH probes. Second,
to clarify if IHC correlates effectively with FISH-analysis.
To evaluate the significance of EGFR determinations, tis-
sues of 206 lung cancer patients were analyzed including
their clinical data.Methods
Patient data and tissues
For the construction of tissue microarray (TMA) blocks, a
collection of 206 lung tumor surgical resection specimens
with NSCLC were obtained after resection from the surgi-
cal department of LungenClinic Grosshansdorf (Table 1).
The retrospective investigation included 100 cases of
adenocarcinoma (ADC), 86 cases of squamous cell car-
cinoma (SCC), 12 cases of large cell carcinoma (LCC),
6 cases of carcinoid tumor and 2 cases of adenosqua-
mous carcinoma. All tumor samples were histologically
classified according to the International Association for
the Study of Lung Cancer/American Thoracic Society/
European Respiratory Society International Multidiscip-
linary classification of lung adenocarcinoma 2011 [12]
and WHO guidelines 2010 [13]. Formalin fixed paraffin
embedded blocks were collected from the Archive of
Clinical & Experimental Pathology, Research Center
Borstel, Germany.Ethics statement
This study was performed in compliance with the ethical
committee of the University of Lübeck (reference number
12–220).Construction of tissue microarrays
For the construction of the TMAs, representative tumor
punches (2 mm in diameter) were taken after charac-
terization with Hematoxylin and Eosin staining (H&E)
as previously described [14]. Two core biopsies from
two different viable parts of each tumor specimen were
transferred using the Beecher manual arrayer (Beecher
instruments, Alpha, Metrix Biotech), in order to enhance
representatives when analyzing the expression of EGFR.
Paraffin embedded A549 cells were used as positive
control.
Table 1 Characteristics of 206 patients with non-small cell
lung cancer
Category Subcategory Results (%)
Age ≥ 65 128 (62.1)
< 65 78 (37.9)
Gender Male 132 (64)
Female 74 (36)
*Smoking status Current 78 (37.9)
Former 30 (14.6)
Never 12 (5.8)
*Asbestos contact Present 17 (8)
Absent 49 (24)
*COPD Present 43 (21)
Absent 5 (2)




ADC subtypes Acinar predominant 38 (18.4)
Solid predominant 25 (12.1)
Papillary predominant 22 (10.8)
Micropapillary predominant 10 (4.9)
Invasive mucinous 3 (1.4)
Lepidic 2 (1)
Grade Well 5 (2.4)
Moderate 82 (39.8)
Poor 119 (57.8)












*History of smoking, contact with asbestos and chronic obstructive pulmonary
disease (COPD) were undetermined in the rest of the patients. Statistical
analysis was done with available data.
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EGFR protein expression was assessed by immunohisto-
chemistry on 2 μm deparaffinized TMA sections, using
four EGFR specific antibodies: the Food and DrugAdministration (FDA) approved Dako EGFR PharmDx
kit (clone 2-18C9, mouse monoclonal, prediluted, DAKO,
Corp., Glostrup, Denmark), Zymed antibody (clone
31G7, mouse monoclonal, 1:30, Zymed laboratories,
San Francisco, CA), Zytomed antibody (clone 2.1E1,
mouse monoclonal, 1:100, Zytomed Systems, Berlin,
Germany) and antibody clone SP84 (rabbit monoclonal,
1:100, Spring Bioscience, CA). The first two clones are
both recognizing the extracellular domain of EGFR and
the mutant form of EGFR (EGFRvIII) by immunohisto-
chemical staining [15] and Western Blot Analysis [16].
Antibody clone 2.1E1 does also recognize the extracellular
part of the EGFR (Zytomed Information). In contrast,
antibody clone SP84 is generated against a synthetic pep-
tide corresponding to C-terminus of the EGFR protein.
Staining procedures were conducted according to man-
ufacturer’s protocols. Antibodies were titrated for optimal
sensitivity. Each TMA paraffin block was cut into multiple
2 μm thick sections, mounted on the positively charged
slides and stained by H&E as well as with every of the
EGFR specific antibodies. In each run of immunostaining,
a separate negative control section was included where
we omitted the primary antibody. For Dako PharmDx
clone 2-18C9, a control slide was provided (Cell line
CAMA-1 with expression level 0 and cell line HT-29
with expression level 2+) which was included in the
IHC staining runs. For Dako PharmDx, 31G7 and 2.1E1,
slides were deparaffinized, hydrated and antigen retrieval
was performed with proteinase K. For SP84, antigen
retrieval was done with 0.1 sodium citrate buffer, pH 6.0
(Merck KGaA, Darmstadt, Germany) microwaved for
4 minutes followed by 30 minutes cooling at RT. Blocking
of endogenous peroxidase was achieved by immersing
the sections in 3% H2O2 for 10 minutes at RT (Dako
PharmDx and Merck KGaA, Darmstadt, Germany),
then washed in TRIS buffer (10× Dako PharmDx kit
wash buffer and 10× Zytomed biosystems wash buffer)
for 2 minutes. Subsequently, sections were incubated with
the different clones of anti-EGFR antibody (Dako PharmDx
negative control reagent and Zytomed biosystems antibody
diluent) for one hour in humidified chambers at RT.
Sections, stained with 31G7 and 2.1E1 were incubated
at RT with Post Block reagent for 15 minutes before HRP
polymer was added for 20 minutes (Zytomed Systems).
For SP84 HRP was incubated for 20 minutes and for Dako
PharmDx (Zytomed systems and Dako labeled polymer
HRP) for 30 minutes respectively. Sections were washed
in TRIS buffer triply for two minutes after incubation
with each reagent. DAB substrate kit (DAB chromogen
and DAB substrate) was used for 15 minutes to
visualize antibody binding. At the end, counterstaining
of the sections was performed in Meyer’s hematoxylin.
Finally, sections were mounted with Pertex (Medite
GmbH, Burgdorf, Germany).
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Specimens were evaluated by light microscopy (Nikon
Eclipse 50i) using low (×100) and high (×200 or ×400)
magnification.
The EGFR expression by IHC was scored using three
different scoring methods:
(A) H-score: as applied in the retrospective FLEX study
[17] is the product of the percentage of cancer cells
positive for EGFR protein on the cell surface
multiplied by the overall intensity of staining
(ranging from 0 to 3+), producing a number from 0
to 300 [9,18].
(B) EGFR expression is defined as positive, if ≥10% of
the tumor cells, using ×10 and ×20 magnification,
show membranous staining of only 2+ and 3+
[6,19,20].
(C) EGFR expression is considered as positive, if ≥10%
of the tumor cells show membranous staining of any
intensity using ×10 and ×20 magnification assessed
by Dako EGFR PharmDx data sheet.
Assessment of EGFR IHC was done for each single
core by two independent observers and the mean of the
two cores was used as a result for the EGFR expression
of each case. In addition, single sections of the original
FFPE blocks were stained with the four EGFR-specific
antibodies of: 1) All cases of LCC; carcinoid and adenos-
quamous carcinoma (tumors with low frequency), 2) 12
cases which lost one of the two cores in the arrays
during IHC, were complemented by staining of whole
cut sections.
Fluorescence in Situ Hybridization
Two different FISH probes of EGFR/Centromere of chro-
mosome 7 (CEN7, CEP7) were used in the study: Dako
Cytomation FISH probe mix (DAKO; Denmark, A/S) and
ZytoLight SPEC EGFR/CEN 7 dual color probe (Zytomed
system, Berlin, Germany). The FISH assay and analysis of
each TMA was done with both probes (n = 412).
Dual color (FISH) was performed on 2 μm thick-sections.
Before hybridization, sections were deparaffinized, dehy-
drated and immersed in citrate buffer (Merck KGaA,
Darmstadt, Germany) pH 6 at 98°C for 15 minutes, fol-
lowed by 2 minutes in distilled water twice. The sections
were air dried and pretreated with pepsin for 5 minutes
before denatured for 10 minutes at 75°C. After overnight
hybridization at 37°C, slides were washed and counter-
stained with 1.5 μg/ml 4′,6′-diamidino-2-phenylindole
(DAPI) mounting medium (Vectashield, Vector labora-
tories, Burlingame, CA) and coverslips were fixed with
nail polish.
Analysis of FISH signals was performed on an epi-
fluorescence microscope Nikon Eclipse 80i H550L(Nikon) with interference filters (AHF Analysentechnik
AG, Tübingen, Germany).
At least 50 non-overlapped interphase nuclei of aver-
age size were scored per core. The selection of the nuclei
was done using the DAPI filter under high magnification
(×600). For each probe, the number of the EGFR and
the chromosome 7 centromere per nuclei were visualized
and scored using the green (FITC) and red (ET Rhod)
filters separately as well as the double red and green filter.
The red filter was used to visualize the EGFR sequence of
Dakocytomation FISH probe mix and the chromosome 7
centromere of Zytolight SPEC EGFR/CEN7 dual color
probe. While the green filter was used to visualize the
EGFR sequence of Zytolight SPEC EGFR/CEN7 dual color
probe and the chromosome 7 centromere of Dako cyto-
mation FISH probe mix.
EGFR gene status results were grouped according to
the Colorado scoring system, classified into six main
categories [21]. 1) disomy: ≤ 2 copies in > 90% of the
cells, 2) low trisomy: ≤ 3 copies in ≥ 40% of cells, 3
copies in 10% – 40% of the cells, ≥ 4 copies in < 10% of
cells, 3) high trisomy: ≤ 3 copies in ⊔ 40% of cells, 3
copies in ≥ 40% of cells, ≥ 4 copies in < 10% of cells, 4)
low polysomy: ≥ 4 copies in 10% – 40% of cells, 5) high
polysomy: ≥ 4 copies in ⊔ 40% of cells, 6) gene amplifi-
cation: specimens with EGFR gene amplification, defined
as: (a): EGFR gene to CEP 7 ratio ≥ 2, (b): small gene
clusters (4 – 10 copies) or innumerable tight gene clus-
ter in > 10% the tumor cells independent of the EGFR
to CEP 7 ratio, (c): larger and brighter EGFR signals
than CEP 7 signals in > 10% of the tumor cells, while
EGFR signals are smaller than the CEP 7 signals in the
adjacent stromal and reactive cells independent of the
EGFR to CEP 7 ratio, (d): > 5 copies of the EGFR signals
in > 10% of tumor cells independent of the EGFR to
CEP 7 ratio. The gene amplification was classified into
low and high levels according to gene to chromosome
ratio ranged between 2.1 and 3 for low amplification
and more than 3 for high amplification [22-24]. Finally,
patients were grouped into EGFR FISH-negative (disomy,
low trisomy, high trisomy, low polysomy) and EGFR
FISH-positive (high polysomy, low amplification, high
amplification). The assessment of the gene copy num-
ber was done for each single core for each case and the
core with the highest copy number was used as a result
of the FISH assay.
As for the IHC, additional single sections of the original
FFPE blocks of representative cases of the tumors with
low frequency and the cases which lost one of the two
cores as assessed by H&E were cut. The tumor area was
selected and marked and one of the FISH probes of
EGFR/CEN 7 was applied to this area for the analysis and
the comparison between the whole cut section and the
cores included in the arrays.
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The statistical analysis was performed using SPSS version
20 (SPSS Inc., Chicago, IL). Associations between the
different variables were done using chi-square test and
Mann-Mann–Whitney U test. The tests were double
sided. Differences were considered statistically significant
for p values <0.05.
Results
Patient characteristics
From the 206 patients, 100 tumors (48.6%) were classified
as ADC, 86 tumors (41.7%) were grouped as SCC, 12
tumors (5.8%) as LCC, and 8 tumors (3.9%) as other
tumors (4 typical carcinoids, 2 atypical carcinoids and 2
adenosquamous carcinoma). Basal characteristics of the
patients and clinicopathological status are summarized
in Table 1. According to WHO 2010, pathological TNM
staging was IA in 22 (10.8%), IIA in 38 (18.4%), IIIA in 53
(25.7%), IB in 46 (22.3%), IIB in 19 (9.2%), IIIB in 20
(9.7%) and IV in 8 (3.9%) patients. Smoking history was
available for 120 cases and classified as current, former
and never smokers [25]. Contact with asbestos was
inquired by asking the patients.
The age of the patients showed statistical significant dif-
ferences for the stage and the grades of tumors (p = 0.034
and p = 0.009). From the patients ≥65 years old, 49
(38.3%) had tumors stage I. 65 (54.6%) had poorly differ-
entiated tumors. Patients <65 years old, 35 (44.9%) had
tumors stage III and 54 (69.2%) had poorly differentiated
tumors. The gender of the patients and different grades of
tumors displayed a significant difference within histo-
logical subtypes: 68 (51.5%) of the male patients had SCC
and 48 (64.9%) of female patients had ADC (p < 0.001).
For the grades of the carcinomas: 66 tumors (55.5%) and
39 tumors (32.8%) of poorly differentiated carcinomas
were ADC and SCC respectively, while 45 tumors (54.9%)
of moderately differentiated cases were SCC (p < 0.001).
Significant differences were found between ADC sub-
types and grades: 24 (36.4%) tumors of poorly differen-
tiated ADC were grouped as acinar predominant. 23
tumors (34.8%) were classified as solid predominant
with mucin production. 8 cases (12.1%) belonged to
papillary predominant, 8 tumors (12.1%) were of micro-
papillary predominant, 2 tumors (3%) of lepidic and 1
case (1.5%) of invasive mucinous. Smoking behavior
was significantly associated with the histological sub-
types and the grades. 36 patients (46.2%) of the current
smokers, and 18 patients (60%) of former smokers had
SCC; while 8 patients (66.7%) of never smokers had ADC
(p = 0.023). 53 SCC (67.9%) were of current smokers. 16
patients (53.3%) of the former smokers had poorly differ-
entiated tumors and 6 patients (50%) of the never smokers
had moderately differentiated tumors (p = 0.001). Contact
with asbestos was significantly associated with stage.10 (55.6%) cases who had contact with asbestos were stage
I and 23 (45.1%) of those who did not have asbestos con-
tact were stage III (p = 0.039). Correlations among clinico-
pathological parameters were not found.Comparison of different EGFR-specific antibodies and
three scoring methods
All of the full sections taken for tumors with a rare inci-
dence and 12 cases which lost one of their two cores
showed the same results as their respective cores in the
arrays. Results of the statistical association of the four
different EGFR specific antibodies and the three different
scoring methods are shown in Table 2.
Intensity of EGFR immunostainings, performed with
the four different antibody clones varied both within one
tumor sample as well as in different tumor specimens
(Figure 1). Analyzing the expression patterns of EGFR
using 3 scoring methods maintained different results for
EGFR positivity (Figure 2). Of 206 patients, analyzed with
Dako pharmDx and evaluated with scoring method (A),
129 tumors samples (62.6%) were allocated as positive.
Analyzing EGFR immunostaining of Dako pharmDx with
scoring method (B) determined 176 patients (85.4%) as
positive and scoring method (C) showed positive EGFR
staining in 184 samples (89.3%).
The outcome of applying, 31G7 using scoring method
(A) yielded 137 EGFR positive tumors (66.5%). Whereas
with scoring method (B), 176 tumors (85.4%) and for
scoring method (C), 185 samples (89.9%) were defined
as EGFR positive.
Antibody 2.1E1 was the most sensitive antibody: we
obtained highest numbers of EGFR-positive tumor sam-
ples using this clone in immunostainings for all of the
three scoring methods. 31G7 and Dako pharmDx show
similar staining intensities independent of the scoring
methods, whereas SP84 showed the lowest sensitivity.
Decreasing the cut off values, lead for all antibody clones
to increasing numbers of EGFR positive immunostainings
(Figure 3).
The degree of agreement determined with score (A)
between Dako PharmDx compared with 31G7, 2.1E1 and
SP84 was 83.5%, 76.7% and 83% respectively. Correlation
between 31G7 and 2.1E1 and between 31G7 and SP84
amounts to 80.6% and 77.2% respectively, and between
2.1E1 and SP84, to 68.4%. For Score (B), the correlation
between Dako PharmDx and 31G7 was 94.2%, for Dako
PharmDx and 2.1E1 it was 93.3% and between Dako
PharmDx and SP84 it was 86.4%. The agreement between
31G7 and 2.1E1 and 31G7 and SP84 was 93.3% and 89.3%
respectively, between 2.1E1 and SP84 it constituted 84.4%.
Scoring with method (C) showed a degree of agreement
between Dako PharmDx, 31G7, 2.1E1 and SP84 of 98.5%,
96.1% and 94.6% respectively. Between 31G7 and 2.1E1
Table 2 EGFR expression evaluated with Dako PharmDx, 31G7, 2.1E1 and SP84 using three different scoring methods; correlation between the four antibodies
31G7 2.1E1 SP84
Positive Negative Positive Negative Positive Negative
Score A
DAKO Positive 116(56.3%) 13(6.3%)* 129(62.6%) 0(0%)* 103(50%) 26(12.6%)*
Negative total 21(10.2%) 137(66.5%) 56(27.2%) 69(33.5%) 48(23.3%) 177(85.9%) 29(14.1%) 29(14.1%) 9(4.4%) 112(54.4%) 68(33%) 94(45.6%)
31G7 Positive 137(66.5%) 0(0%)* 101(49%) 36(17.5%)*
Negative total 40(19.4%) 177(85.9%) 29(14.1%) 29(14.1%) 11(5.3%) 112(54.3%) 58(28.2%) 94(45.7%)
2.1E1 Positive 112(54.3%) 65(31.6%)*
Negative total 0(0%) 112(54.3%) 29(14.1%) 94(45.7%)
Score B
DAKO Positive 170(82.5%) 6(2.9%)* 175(85%) 1(0.4%)* 154(74.7%) 22(10.7%)*
Negative total 6(2.9%) 176(85.4%) 24(11.7%) 30(14.6%) 13(6.3%) 188(94.3%) 17(8.3%) 18(8.7%) 6(2.9%) 160(77.6%) 24(11.7%) 46(22.4%)
31G7 Positive 175(85%) 1(0.4%)* 157(76.2%) 19(9.2%) *
Negative total 13(6.3%) 188(91.3%) 17(8.3%) 18(8.7%) 3(1.5%) 160(77.7%) 27(13.1%) 46(22.3%)
2.1E1 Positive 158(76.6%) 30(14.6%)*
Negative total 2(1%) 160(77.6%) 16(7.8%) 46(22.4%)
Score C
DAKO Positive 183(88.8%) 1(0.5%)* 183(88.8%) 1(0.5%)* 177(85.9%) 7(3.4%)*
Negative total 2(1%) 185(89.8%) 20(9.7%) 21(10.2%) 7(3.4%) 190(92.2%) 15(7.3%) 16(7.8%) 4(2.0%) 181(87.9%) 18(8.7%) 25(12.1%)
31G7 Positive 185(89.8%) 0(0%)* 178(86.4%) 7(3.4%)*
Negative total 5(2.4%) 190(92.2%) 16(7.8%) 16(7.8%) 3(1.5%) 181(87.9%) 18(8.7%) 25(12.1%)
2.1E1 Positive 179(86.9%) 11(5.3%)*

















Figure 1 Immunohistochemical EGFR staining with four different antibodies showing differences in levels of EGFR expression in
the same specimen of a squamous cell carcinoma (SSC) (original magnification × 400). (A) Staining intensity with Dako PharmDx 2+,
(B) Staining intensity with 31G7 2+, (C) Staining intensity with 2.1E1 3+, (D) Staining intensity with SP84 1+.
Figure 2 Different cases of adenocarcinomas (ADC) showing different results using scores A, B, C (original magnification × 400).
(A) Positive with score C, negative in A and B (intensity 1 in 100% of tumor cells H-score ⊔ 200). (B) Positive with score B and C and negative in
score A (Tumor cells show different intensities: 2 in 40%, 1 in 40% and 0 in 20% H-score ⊔ 200). (C) and (D) Positive in all scores: C) intensity 2 in
100% of tumors cells H-score = 200, D) intensity 3 in 100% of tumor cells H-score = 300).
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Figure 3 Assessment of Dako PharmDx, 31G7, 2.1E1 and SP84
using three different scoring methods.
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ively and between 2.1E1 and SP84 it was 93.7% (Table 2).
All antibody clones investigated showed different de-
grees of agreement concerning the EGFR expression
when analyzed by the three different scoring methods.
For the Dako PharmDx antibody clone, the correlation
between scoring method (A) and (B) was 73.3%, between
(A) and (C) it was 70.1% and between (B) and (C) 95.7%.
Antibody clone 31G7 depicted the degree of agreement
between scoring method (A) and (B) of 77.8%, between
(A) and (C) of 74.1% and between (B) and (C) of 95.1%.
For antibody clone 2.1E1 correlation between scoring
method (A) and (B) accounted to 94.1%, between (A)
and (C) to 93.2%, and to 98.9% between scoring method
(B) and (C). Antibody clone SP84 showed the degree of
agreement between scoring method (A) and (B) of 70%,
between (A) and (C) of 61.9% and between scoring
method (B) and (C) of 88.4% (Table 2).
Relationship between EGFR protein expression and
clinicopathological data
The results for the four EGFR specific antibodies obtained
by immunostaining and analyzed by three different
scoring methods varied within the histological types of
NSCLC.
The four antibody clones showed diverse intensities of
staining and therefore different EGFR expression patterns
within the same specimen leading to different IHC results
(Figure 1).
Dependent of the scoring method, performed, assessment
of EGFR expression varies. Different ADC tumor samples
show varying results in EGFR expression according to the
different scoring systems (A), (B) and (C) (Figure 2).
EGFR expression evaluated with scoring method (A)
showed for all of the four antibodies fewer numbers of
EGFR positive tumor samples for all of the four antibodies
in SCC and ADC than evaluated with method (B) and (C).
Data are shown in Table 2. Scoring with method (C)
features more EGFR-positive tumor samples in ADC thanin SCC. EGFR protein expression evaluated with 31G7,
scored with method (B) and 2.1E1 scored with method
(A) showed a significant association with tumor differenti-
ation (p = 0.041 and p = 0.029).
An association between EGFR expression and tumor
grade was shown when evaluation was performed with
31G7 using scoring method (B) (p = 0.02) and 2.1E1
employing scoring method (A) (p = 0.009) and (C)
(p = 0.047). Smoking behavior correlates with EGFR
expression when evaluated by IHC with antibody SP84
using scoring method (C) (p = 0.014).
EGFR protein expression determined with the four
antibodies was not associated with age, sex, tumor stage
and tumor or lymph node status.
EGFR Fluorescence in Situ Hybridization
FISH analysis for EGFR gene copy numbers showed exactly
the same results for both probes (Dako Cytomation FISH
probe mix and ZytoLight SPEC) (Figure 4). Of 206 tumor
samples, 84 tumors (40.8%) showed disomy, 36 tumors
(17.5%) low trisomy, 22 tumor samples (10.7%) high tri-
somy, 22 tumor samples (10.7%) low polysomy, 28 patients
(13.6%) high polysomy, 5 tumors (2.4%) low amplification,
and 9 patients (4.4%) high amplification. Altogether,
positive FISH results including high amplification, low
amplification and high polysomy were demonstrated in
42 cases (20.4%).
Association between EGFR copy number and
clinicopathological data
FISH positivity was more frequently in ADC than in
SCC and LCC (23 (11.2%) vs 17 (8.3%) vs 2 (1%). Differ-
ences did not reach statistical significance (p = 0.567)
(Table 3). Thus, the existence of amplification did not
correlate with the histological subtypes.
But, for ADC an association between FISH positivity
and subclassification was found. EGFR FISH positivity
was evaluated for 11 (5.4%) tumors that were of acinar
predominant subtype, 2 (1%) of solid predominant, 7
(3.4%) of papillary predominant, 1 (0.5%) of micropapillary
predominant and 2 (1%) of lepidic subtype (p = 0.029)
(Table 4).
The distribution of FISH patterns was not associated
with age, sex, smoking, contact of asbestos or COPD,
grade, stage, size of lymph nodes or tumor size (Table 3).
Association between EGFR protein expression and EGFR
copy number
There was a significant (Fisher’s exact test) association
between IHC positivity and EGFR gene copy number
per cell for all of the four investigated antibody clones
independent of the applied scoring method, except for
SP84 analyzed with score A and B (Table 5). Dako
PharmDx, 31G7 and 2.1E1, evaluated by three different
Figure 4 FISH analysis with two different EGFR-specific FISH probes. A, B, C, D: Dako Cytomation FISH probe mix (EGFR: red, CEN7: green),
E, F, G, H: ZytoLight SPEC EGFR/CEN7 dual probe (EGFR: green, CEN7: red), (magnification × 630) A, E: balanced disomy, B, F: balanced trisomy,
C, G: low amplification, D, H: high amplification.
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analysis. Immunostainings with 31G7, evaluated with
scoring method B showed the highest concordance with
FISH analysis (Table 5).
Discussion
Personalized therapies are based upon the exact deter-
mination, characterization and quantification of the
according target molecules. The significance of the as-
sessment of EGFR gene copy number and EGFR protein
expression as biomarkers to predict therapy responders
as well as the selection of patients who might poten-
tially benefit from EGFR targeted therapies was demon-
strated by different studies [21,26-28] and also the
FLEX study [9,17]. Additionally, the predicitive value of
EGFR as biomarker was previously shown [29]. As a
methodological base to identify lung cancer patients
who might benefit from EGFR-specific antibodies, we
studied the relationship between EGFR-expression
on protein level and gene copy numbers assessed by
FISH.
As part of a broad investigation, we analyzed EGFR
expression in tumor samples of NSCLC patients by IHC
using four different EGFR specific antibody clones and
three scoring methods and correlated these data with
FISH analysis. The comprehensive comparison of Dako
PharmDx, 31G7, 2.1E1 and SP84 analyzed by different
scoring methods has not previously been published just
as matching two different FISH probes. Dako PharmDx
and 31G7 are frequently used antibodies for EGFR-
expression studies [6,9]. 2.1E1 and SP84 are both
commercially available and therefore they are also
candidates to be applied in the characterization of clinical
routine paraffine sections to evaluate EGFR-expression.The evaluation of the four antibody clones demonstrated
the highest degree of agreement between Dako PharmDx
and 31G7 amounting to 83.5% applying scoring method
(A), to 94.2% with score (B), and to 98.5% with score (C)
which was previously also shown by Lee et al. [18]. Both
antibodies show similar sensitivity in EGFR staining in
formalin fixed NSCLC specimens. 2.1E1 showed the high-
est sensitivity when scoring methods (A) (85.9%) and (C)
(92.9%) were used. Dako PharmDx and 31G7 have nearly
the same EGFR staining intensity as previously described
by Lee et al. [18], even after evaluation with the three
scoring methods.
SP84 showed weaker binding to the EGFR, independent
of the scoring method. That might be due to the fact, that
SP84 is generated against a synthetic peptide corre-
sponding to C-terminus of human EGFR protein, whereas
2.1E1, Dako PharmDx and 31G7 recognize the extracellu-
lar domain of the molecule.
Our results demonstrated significant correlations for
EGFR staining results between the four antibodies
(p < 0.001). These data are in compliance with Hirsch
et al. [6]. In this study, Dako PharmDx and 31G7 and two
different scoring systems were compared. They postulated
that lower cut off points for Dako PharmDx provide the
best discrimination between EGFR positive and negative
patients and therefore generate more accurate prediction
of survival dependent on gefitinib treatment.
In accordance with other studies [19,21,30], we showed
a more frequent positive EGFR expression for all of the
four antibodies in SCC than in ADC when scoring
method (A) was executed. Just for 2.1E1, scored with
method A, positive EGFR expression was equal distributed
between SCC and ADC. Whereas evaluation with scoring




Dako pharmDx 31G7 2.1E1 SP84 FISH
A B C A B C A B C A B C +
Age ≥65 128(62) 84(40.8) 112(54.4) 118(57.3) 90(43.7) 112(54.4) 117(56.8) 112(54.4) 119(57.8) 119(57.5) 72(35) 98(47.6) 113(54.9) 26(12.6)
<65 78(38) 45(21.8) 64(31.1) 66(32) 47(22.8) 64(31.1) 68(33) 65(31.6) 69(33.5) 71(34.5) 40(19.4) 62(30.1) 68(33) 16(7.8)
P value 0.299 0.312 0.105 0.171 0.312 0.350 0.416 0.312 0.789 0.564 0.731 0.829 1
Sex Male 132(64) 81(39.3) 115(55.8) 121(58.7) 85(41.3) 116(56.3) 123(59.7) 115(55.8) 124(60.2) 125(60.7) 75(36.4) 109(52.9) 120(58.3) 24(11.7)
Female 74(36) 48(23.3) 61(29.6) 63(30.6) 52(25.2) 60(29.1) 62(30.1) 62(30.1) 64(31.1) 65(31.6) 37(18) 51(24.8) 61(29.6) 18(8.7)
P value 0.655 0.412 0.163 0.443 0.218 0.052 0.535 0.077 0.103 0.383 0.036 0.080 0.368
Histology ADC 100(48.6) 53(25.7) 82(39.8) 88(42.7) 58(28.2) 81(39.3) 89(43.2) 83(40.3) 90(43.7) 91(44.2) 42(20.4) 67(32.5) 85(41.3) 23(11.2)
SCC 86(41.7) 69(33.5) 82(39.8) 84(40.8) 70(34) 83(40.3) 84(40.8) 83(40.3) 84(40.8) 85(41.3) 65(31.6) 82(39.8) 84(40.8) 17(8.3)
LCC 12(5.8) 6(2.9) 9(4.4) 9(4.4) 7(3.4) 9(4.4) 9(4.4) 8(3.9) 9(4.4) 9(4.4) 5(2.4) 9(4.4) 9(4.4) 2(1)
Other 8(3.9) 1(0.5) 3(1.5) 3(1.5) 2(1) 3(1.5) 3(1.5) 3(1.5) 5(2.4) 5(2.4) 0(0) 2(1) 3(1.5) 0(0)
P value 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.001 0.000 0.000 0.000 0.000 0.567
ADC subtypes Acinar 38(18.4) 21(21) 30(30) 33(33) 24(24) 32(32) 33(33) 31(31) 33(33) 33(33) 16(16) 26(26) 34(34) 11(11)
Solid 25(12.1) 11(11) 19(19) 21(21) 12(12) 19(19) 22(22) 19(19) 22(22) 22(22) 8(8) 16(16) 21(21) 2(2)
Papillary 22(10.8) 15(15) 21(21) 22(22) 16(16) 21(21) 22(22) 22(22) 22(22) 22(22) 12(12) 17(17) 20(20) 7(7)
Micro papillary 10(4.9) 4(4) 8(8) 8(8) 4(4) 6(6) 8(8) 8(8) 9(9) 9(9) 4(4) 5(5) 6(6) 1(1)
Invasive mucinous 3(1.4) 1(19 2(2) 2(2) 1(1) 2(2) 2(2) 2(2) 2(2) 2(2) 1(1) 2(2) 2(2) 2(2)
Lepidic 2(1) 1(1) 2(2) 2(2) 1(1) 1(1) 2(2) 1(1) 2(2) 3(3) 1(1) 1(1) 2(2) 0(0)
P value 0.516 0.348 0.181 0.302 0.041 0.201 0.029 0.258 0.499 0.751 0.438 0.189 0.029
Grade Well 5(2.4) 2(1) 3(1.5) 3(1.5) 2(1) 2(1) 3(1.5) 2(1) 3(1.5) 3(1.5) 2(1) 2(1) 3(1.5) 1(0.5)
Moderate 82(39.8) 55(26.7) 71(34.5) 73(35.4) 60(29.1) 72(35) 74(35.9) 74(35.9) 76(36.9) 77(37.4) 46(22.3) 67(32.5) 72(35) 17(8.3)
poor 119(57.8) 72(35) 102(49.5) 108(52.4) 75(36.4) 102(49.5) 108(52.4) 101(49) 109(52.9) 110(53.4) 64(31.1) 91(44.2) 106(51.5) 24(11.7)
P value 0.371 0.268 0.107 0.148 0.020 0.126 0.009 0.62 0.047 0.789 0.075 0.155 1
Tumor size T1 39(18.9) 24(11.7) 30(14.6) 31(15) 25(12.1) 31(15) 32(15.5) 30(14.6) 33(16) 34(16.5) 20(9.7) 28(13.6) 31(15) 5(2.4)
T2 115(55.9) 71(34.5) 99(48.1) 105(51) 78(37.9) 99(48.1) 104(50.5) 100(48.5) 104(50.5) 105(51) 61(29.6) 90(43.7) 102(49.5) 24(11.7)
T3 32(15.5) 21(10.2) 30(14.6) 31(15) 20(9.7) 29(14.1) 31(15) 28(13.6) 31(15) 31(15) 17(8.3) 24(11.7) 29(14.1) 7(3.4)
T4 20(9.8) 13(6.3) 17(8.3) 17(8.3) 14(6.8) 17(8.3) 18(8.7) 19(9.2) 20(9.7) 20(9.7) 14(6.8) 18(8.7) 19(9.2) 6(2.9)
P value 0.982 0.271 0.080 0.919 0.615 0.234 0.293 0.181 0.309 0.539 0.444 0.362 0.449
Lymph node N0 99(48) 66(32) 82(39.8) 86(41.7) 66(32) 82(39.8) 86(41.7) 82(39.8) 88(42.7) 88(42.7) 54(26.2) 75(36.4) 84(40.8) 14(6.8)
N1 49(23.8) 30(14.6) 43(20.9) 46(22.3) 31(15) 43(20.9) 46(22.3) 44(21.4) 46(22.3) 46(22.3) 26(12.6) 39(18.9) 44(21.4) 13(6.3)
N2 43(20.9) 24(11.7) 38(18.4) 38(18.4) 27(13.1) 37(18) 39(18.9) 37(18) 40(19.4) 41(19.9) 25(12.1) 33(16) 39(18.9) 12(5.8)
N3 15(7.3) 9(4.4) 13(6.3) 14(6.8) 13(6.3) 14(6.8) 14(6.8) 14(6.8) 14(6.8) 15(7.3) 7(3.4) 13(6.3) 14(6.8) 3(1.5)
















Table 3 ᅟ (Continued)
Stage I 68(33) 45(21.8) 57(27.7) 60(29.1) 47(22.8) 59(28.6) 60(29.1) 59(28.6) 62(30.1) 62(30.1) 36(17.5) 53(25.7) 58(28.2) 8(3.9)
II 57(27.7) 32(15.5) 46(22.3) 50(24.3) 34(16.5) 44(21.4) 49(23.8) 45(21.8) 49(23.8) 49(23.8) 27(13.1) 40(19.4) 47(22.8) 13(6.3)
III 73(35.4) 45(21.8) 66(32) 67(32.5) 50(24.3) 66(32) 68(33) 65(31.6) 69(33.5) 71(34.5) 44(21.4) 60(29.1) 68(33) 18(8.7)
IV 8(3.9) 7(3.4) 7(3.4) 7(3.4) 6(2.9) 7(3.4) 8(3.9) 8(3.9) 8(3.9) 8(3.9) 5(2.4) 7(3.4) 8(3.9) 3(1.5)
P value 0.337 0.406 0.771 0.635 0.192 0.493 0.317 0.380 0.093 0.494 0.403 0.194 0.095
Smoking behavior Current 78(56.1) 52(43.3) 71(59.2) 72(60) 55(45.8) 70(58.3) 72(60) 71(59.2) 72(60) 72(60) 44(36.7) 67(55.8) 72(60) 16(13.3)
Former 30(21.6) 22(18.3) 27(22.5) 28(23.3) 23(19.2) 27(22.5) 29(24.2) 27(22.5) 29(24.2) 29(24.2) 19(15.8) 26(21.7) 29(24.2) 4(3.3)
Never 12(8.6) 6(5) 9(7.5) 9(7.5) 6(5) 9(7.5) 9(7.5) 9(7.5) 9(7.5) 10(8.3) 5(4.2) 7(5.8) 8(6.7) 2(1.7)
P value 0.342 0.254 0.150 0.254 0.373 0.078 0.254 0.078 0.368 0.494 0.055 0.014 0.729
Asbestos contact Present 18(20.5) 14(20.3%) 17(24.6) 17(24.6) 14(20.3) 17(24.6%) 17(24.6) 16(23.2) 17(24.6%) 17(24.6) 12(17.4) 16(23.2%) 18(26.1) 3(4.3)
Absent 51(58) 37(53.6%) 45(65.2) 45(65.2) 38(55.1) 44(63.8%) 46(66.7) 44(63.8) 46(66.7%) 46(66.7) 28(40.5) 40(58%) 46(66.7) 14(20.3)
















Table 4 Association between ADC subtypes and FISH patterns
D LT HT LP HP LA HA
Acinar 15(7.3%) 6(2.9%) 1(1%) 5(2.4%) 10(4.9%) 0(0%) 1(0.5%)
Solid 6(2.9%) 8(3.9%) 5(2.4%) 4(1.9%) 2(1%) 0(0%) 0(0%)
Papillary 6(2.9%) 2(1%) 2(1%) 5(2.4%) 5(2.4%) 1(0.5%) 1(0.5%)
Micropapillary 7(3.4%) 0(0%) 2(1%) 0(0%) 1(0.5%) 0(0%) 0(0%)
Invasivemucinous 2(1%) 0(0%) 0(0%) 1(0.5%) 0(0%) 0(0%) 0(0%)
Lepidic 0(0%) 0(0%) 0(0%) 0(0%) 1(0.5%) 1(0.5%) 0(0%)
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http://www.diagnosticpathology.org/content/9/1/165expression in ADC than in SCC. Scoring with method (B)
showed a similar EGFR expression in SCC and ADC for
Dako PharmDx and 31G7. 2.1E1 features a higher EGFR
expression in ADC than in SCC, whereas SP84 indicates
an EGFR overexpression more frequently in SCC than in
ADC. Although, there were no significant differences in
EGFR expression between the ADC subtypes according to
IASLC classification [31], EGFR overexpression was most
frequently in the acinar subtype, followed by the papilary




























Total 42(20.4%the four antibodies and the three scoring methods. Warth
et al. had previously shown that the novel histologic
IASLC/ATS/ERS classification of pulmonary ADC has
prognostic impact [32]. The significance of EGFR expres-
sion on protein level as prognostic and also as predictive
marker in NSCLC is emphasized by Travis et al. [12] and
necessitates further studies to obtain more insights in the
correlation of EGFR expression within ADC subtypes.
According to the Colorado scoring system of Varella-
Garcia et al. [24] and Cappuzzo et al. [22], both EGFRg methods and FISH analysis
Total P
valueNegative
) 95(46.1%) 129(62.6%) 77(37.4%) 0.007
69(33.5%)
) 135(65.5%) 176(85.4%) 30(14.6%) 0.012
29(14.1%)
) 142(68.9%) 184(89.3%) 22(10.7%) 0.009
22(10.7%)
) 61(29.6%) 95(46.1%) 111(53.9%) 0.028
103(50%)
) 134(65%) 176(85.4%) 30(14.6%) 0.001
30(14.6%)
) 143(69.4%) 185(89.8%) 21(10.2%) 0.009
21(10.2%)
) 136(66%) 177(85.9%) 29(14.1%) 0.012
28(13.6%)
) 146(70.9%) 188(91.3%) 18(8.7%) 0.027
18(8.7%)
) 148(71.8%) 190(92.2%) 16(7.8%) 0.046
16(7.8%)
) 87(42.2%) 112(54.3%) 94(45.7%) 0.491
77(37.4%)
123(59.7%) 160(77.7%) 46(22.3%) 0.095
41(19.9%)
) 139(67.5%) 181(87.9%) 25(12.1%) 0.003
25(12.1%)
) 164(79.6%)
Gaber et al. Diagnostic Pathology 2014, 9:165 Page 13 of 15
http://www.diagnosticpathology.org/content/9/1/165specific FISH probes showed exactly the same results.
The consistency of both FISH probes according to the
results of allocation into the same subtypes of disomy,
low and high trisomy, low and high polysomy and ampli-
fication is disambiguate. To our knowledge, this is the
first study that compared the results of two different
FISH probes. These data underline that FISH analysis is
a reliable and reproducible technique to evaluate EGFR
gene amplification in comparison to the determination
of EGFR status by IHC.
In this study, 42 tumor samples (20.4%) were FISH
positive as represented by high polysomy (13.6%), low
amplification (42.4%) and high amplification (4.3%).
These results are in concordance with Lee et al. [18] and
Hirsch et al. [21]. In our study, EGFR positivity was
more frequent in ADC than in SCC (11.2% vs. 8.3%)
which is also in accordance with Lee et al. [18] but is
contrary to the results of Hirsch et al. [21] in which
EGFR amplification is more frequent in SCC.
We were able to show significant differences concerning
EGFR FISH patterns in adenocarcinoma subtypes (p =
0.029). These results differ from the study of Soma et al.
[33] in which EGFR gene amplification did not differ
among predominant patterns. Our results demonstrated an
explicit relationship between EGFR gene copy number and
ADC subtypes, thus warrant further investigations.
Comparison of IHC data of Dako PharmDx, 31G7 and
2.1E1 and the results obtained by FISH analysis showed
strong association between both methods. 31G7 showed
the highest correlation to FISH analysis when evaluated
with score B (p = 0.001). Whereas IHC data performed
with SP84 showed significant correlation only after
scoring with method C. Again, this antibody clone is out
of band and the reason therefore might be the different
epitope which is recognized by SP84.
FISH analysis in combination with IHC independent
of the choice of antibody Dako PharmDx, 31G7 and
2.1E1, and regardless of which scoring method, currently
seems to be the best approach to identify patients that
might profit of EGFR target therapies. The standardization
of EGFR status determination is compulsory. Our advice
is to use Dako PharmDx, 31G7 or 2.1E1 in IHC and
confirm these data by FISH analysis to facilitate more
patients for EGFR specific treatments concerning their
EGFR expression pattern. However these findings have
to be correlated with clinical outcomes following treat-
ment with EGFR-antibodies in order to validate the
predictive quality of the EGFR expression status.
Conclusions
In summary, the message of this study is: different
methods exist for the evaluation of EGFR expression
leading to different results. Highest concordance with
FISH is shown for antibody clone 31G7, evaluated withscore B (p = 0.001). Thus, IHC performed with this anti-
body might be used as standard for the determination
of EGFR expression. Additionally, we showed, that there is
no correlation between EGFR expression and histo-
logical subtypes and clinicopathological data. For future
treatment-studies investigating the efficacy of EGFR
specific antibodies, the choice of a standardized antibody
for EGFR-IHC is therefore crucial to ensure the compar-
ability of EGFR-expression results.
In a next step we will compare formalin fixed paraffin
embedded versus HOPE fixed lung tissue with intention
to identify differences between the four investigated
antibodies between these two different fixation methods.
Further investigations will focus on the evaluation of
EGFR expression on mRNA-level by real time PCR and
western blot analysis to validate these data. Additionally,
mutation analysis of compound EGFR mutations [34]
and EGFR downstream genes [35] will be performed in
order to predict response rates to TKI therapies. Previous
studies figured out, that phosphorylation of EGFR is also
associated with poor outcome in NSCLC [36]. Surpris-
ingly, 10%-20% of NSCLC patients with EGFR wild type
NSCLC also benefit from TKIs [37,38]. Therefore, it is
crucial to combine all these EGFR characterization
methods to get more insight into the correlation of EGFR
expression on protein level, gene amplification, activation
status and response rates to EGFR selective therapeutics.
For this purpose, Short Term Stimulation of Tissue
(STST) could be performed. All these comprehensive
investigations have high relevance to improve the iden-
tification of more patients who might profit of EGFR
specific therapies in future.
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